{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T01:29:15Z","timestamp":1771637355726,"version":"3.50.1"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2017,11,30]],"date-time":"2017-11-30T00:00:00Z","timestamp":1512000000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,4,1]]},"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n The management of localized extremity soft tissue sarcomas (STS) is challenging and the role of pre- and postoperative chemotherapy is unclear and debated among experts.<\/jats:p>\n <\/jats:sec>\n \n Materials and Methods<\/jats:title>\n Medical oncology experts of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group were asked to participate in this survey on the use of pre- and postoperative chemotherapy in STS. Experts from 12 centers in Belgium, France, Germany, Great Britain, Italy, Switzerland, and The Netherlands agreed to participate and provided their treatment algorithm. Answers were converted into decision trees based on the objective consensus methodology. The decision trees were used as a basis to identify consensus and discrepancies.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Several criteria used for decision-making in extremity STS were identified: chemosensitivity, fitness, grading, location, and size. In addition, resectability and resection status were relevant in the pre- and postoperative setting, respectively. Preoperative chemotherapy is considered in most centers for marginally resectable tumors only. Yet, in some centers, neoadjuvant chemotherapy is used routinely and partially combined with hyperthermia. Although most centers do not recommend postoperative chemotherapy, some offer this treatment on a regular basis. Radiotherapy is an undisputed treatment modality in extremity STS.<\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n Due to lacking evidence on the utility of pre- and postoperative chemotherapy in localized extremity STS, treatment strategies vary considerably among European experts. The majority recommended neoadjuvant chemotherapy for marginally resectable grade 2\u20133 tumors; the majority did not recommend postoperative chemotherapy in any setting.<\/jats:p>\n <\/jats:sec>\n \n Implications for Practice<\/jats:title>\n The management of localized extremity soft tissue sarcomas (STS) is challenging and the role of pre- and postoperative chemotherapy is unclear and debated among experts. This study analyzed the decision-making process among 12 European experts on systemic therapy for STS. A wide range of recommendations among experts regarding the use of perioperative chemotherapy was discovered. Discrepancies in the use of decision criteria were also uncovered, including the definition of what constitutes high-risk cancer, which is a basis for many to recommend chemotherapy. Before any standardization is possible, a common use of decision criteria is necessary.<\/jats:p>\n <\/jats:sec>","DOI":"10.1634\/theoncologist.2017-0391","type":"journal-article","created":{"date-parts":[[2017,11,30]],"date-time":"2017-11-30T21:05:23Z","timestamp":1512075923000},"page":"461-467","source":"Crossref","is-referenced-by-count":30,"title":["Pre- and Postoperative Chemotherapy in Localized Extremity Soft Tissue Sarcoma: A European Organization for Research and Treatment of Cancer Expert Survey"],"prefix":"10.1093","volume":"23","author":[{"given":"Christian","family":"Rothermundt","sequence":"first","affiliation":[{"name":"Division of Medical Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Galina F.","family":"Fischer","sequence":"additional","affiliation":[{"name":"Division of Radio Oncology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Bauer","sequence":"additional","affiliation":[{"name":"Sarcoma Centre, University Hospital, Essen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Yves","family":"Blay","sequence":"additional","affiliation":[{"name":"L\u00e9on B\u00e9rard Centre, Lyon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viktor","family":"Gr\u00fcnwald","sequence":"additional","affiliation":[{"name":"Clinic for Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Medical School Hannover, Hannover, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoine","family":"Italiano","sequence":"additional","affiliation":[{"name":"Early Phase Trials and Sarcoma Units, Institut Bergoni\u00e9, Bordeaux, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernd","family":"Kasper","sequence":"additional","affiliation":[{"name":"Tumor Centre and Centre of Oncology, University Hospital Mannheim, Mannheim, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Attila","family":"Koll\u00e1r","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, University Hospital Bern, Bern, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars H.","family":"Lindner","sequence":"additional","affiliation":[{"name":"Sarcoma Centre, University Hospital Munich - Campus Grosshadern, Munich, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aisha","family":"Miah","sequence":"additional","affiliation":[{"name":"Sarcoma Unit, The Royal Marsden NHS Foundation Trust, London, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Sleijfer","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Stacchiotti","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, National Tumor Institute, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul Martin","family":"Putora","sequence":"additional","affiliation":[{"name":"Division of Radio Oncology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland"},{"name":"Department of Radiation Oncology, lnselspital, Bern University Hospital, University of Bern, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2017,11,30]]},"reference":[{"key":"2021122510435114600_onco12335-bib-0001","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.4065\/82.11.1409","article-title":"Sarcoma","volume":"82","author":"Skubitz","year":"2007","journal-title":"Mayo Clin Proc"},{"key":"2021122510435114600_onco12335-bib-0002","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21387","article-title":"Cancer statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"2021122510435114600_onco12335-bib-0003","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1016\/j.ejca.2011.08.008","article-title":"Rare cancers are not so rare: The rare cancer burden in Europe","volume":"47","author":"Gatta","year":"2011","journal-title":"Eur J Cancer"},{"key":"2021122510435114600_onco12335-bib-0004","first-page":"10","author":"WHO classification of tumors of soft tissue and bone","year":"2013"},{"key":"2021122510435114600_onco12335-bib-0005","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1056\/NEJMra041866","article-title":"Soft-tissue sarcomas in adults","volume":"353","author":"Clark","year":"2005","journal-title":"N Engl J Med"},{"key":"2021122510435114600_onco12335-bib-0006","first-page":"iii102","volume-title":"ESMO\/European Sarcoma Network Working Group","year":"2014"},{"key":"2021122510435114600_onco12335-bib-0007","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1200\/JCO.1998.16.1.197","article-title":"Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity","volume":"16","author":"Yang","year":"1998","journal-title":"J Clin Oncol"},{"key":"2021122510435114600_onco12335-bib-0008","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1016\/S0140-6736(02)09292-9","article-title":"Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: A randomised trial","volume":"359","author":"O'Sullivan","year":"2002","journal-title":"Lancet"},{"key":"2021122510435114600_onco12335-bib-0009","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/978-3-319-40618-3","volume-title":"AJCC Cancer Staging Manual. 8th ed. Cham","author":"Amin","year":"2017"},{"key":"2021122510435114600_onco12335-bib-0010","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/1097-0142(19860715)58:2<306::AID-CNCR2820580216>3.0.CO;2-7","article-title":"Reproducibility of a histopathologic grading system for adult soft tissue sarcoma","volume":"58","author":"Coindre","year":"1986","journal-title":"Cancer"},{"key":"2021122510435114600_onco12335-bib-0011","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(16)00010-3","article-title":"Development and external validation of two nomograms to predict overall survival and occurrence of distant metastases in adults after surgical resection of localised soft-tissue sarcomas of the extremities: A retrospective analysis","volume":"17","author":"Callegaro","year":"2016","journal-title":"Lancet Oncol"},{"key":"2021122510435114600_onco12335-bib-0012","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1016\/j.ejca.2015.07.025","article-title":"Age and case mix-standardised survival for all cancer patients in europe 1999\u20132007: Results of EUROCARE-5, a population-based study","volume":"51","author":"Baili","year":"2015","journal-title":"Eur J Cancer"},{"key":"2021122510435114600_onco12335-bib-0013","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/S1470-2045(12)70346-7","article-title":"Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): A multicenter randomised controlled trial","volume":"13","author":"Woll","year":"2012","journal-title":"Lancet Oncol"},{"key":"2021122510435114600_onco12335-bib-0014","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1200\/JCO.2001.19.5.1238","article-title":"Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: Results of the Italian randomized cooperative trial","volume":"19","author":"Frustaci","year":"2001","journal-title":"J Clin Oncol"},{"key":"2021122510435114600_onco12335-bib-0015","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1016\/S0140-6736(97)08165-8","article-title":"Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: Meta-analysis of individual data. Sarcoma meta-analysis collaboration","volume":"350","year":"1997","journal-title":"Lancet"},{"key":"2021122510435114600_onco12335-bib-0016","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/cncr.23592","article-title":"A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma","volume":"113","author":"Pervaiz","year":"2008","journal-title":"Cancer"},{"key":"2021122510435114600_onco12335-bib-0017","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s12874-017-0400-y","article-title":"Applied swarm-based medicine: Collecting decision trees for patterns of algorithms analysis","volume":"17","author":"Panje","year":"2017","journal-title":"BMC Med Res Methodol"},{"key":"2021122510435114600_onco12335-bib-0018","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1186\/s13014-014-0270-y","article-title":"Objective consensus from decision trees","volume":"9","author":"Putora","year":"2014","journal-title":"Radiat Oncol"},{"key":"2021122510435114600_onco12335-bib-0019","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1634\/theoncologist.2015-0145","article-title":"Algorithms in the first-line treatment of metastatic clear cell renal cell carcinoma\u2013Analysis using diagnostic nodes","volume":"20","author":"Rothermundt","year":"2015","journal-title":"The Oncologist"},{"key":"2021122510435114600_onco12335-bib-0020","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00345-016-1903-6","article-title":"Second-line treatment for metastatic clear cell renal cell cancer: Experts' consensus algorithms","volume":"35","author":"Rothermundt","year":"2017","journal-title":"World J Urol"},{"key":"2021122510435114600_onco12335-bib-0021","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s11060-015-1957-0","article-title":"Patterns of care in recurrent glioblastoma in Switzerland: A multicenter national approach based on diagnostic nodes","volume":"126","author":"Hundsberger","year":"2016","journal-title":"J Neurooncol"},{"key":"2021122510435114600_onco12335-bib-0022","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/S1470-2045(17)30334-0","article-title":"Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): An international, open-label, randomised, controlled, phase 3, multicenter trial","volume":"18","author":"Gronchi","year":"2017","journal-title":"Lancet Oncol"},{"key":"2021122510435114600_onco12335-bib-0023","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S1470-2045(10)70071-1","article-title":"Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: A randomised phase 3 multicenter study","volume":"11","author":"Issels","year":"2010","journal-title":"Lancet Oncol"},{"key":"2021122510435114600_onco12335-bib-0024","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdw435.52","article-title":"Full-dose neoadjuvant anthracycline and ifosfamide chemotherapy is associated with a relapse free survival (RFS) and overall survival (OS) benefit in localized high-risk adult soft tissue sarcomas (STS) of the extremities and trunk wall: Interim analysis of a prospective randomized trial","volume":"27","author":"Gronchi","year":"2016","journal-title":"Ann Oncol"},{"key":"2021122510435114600_onco12335-bib-0025","doi-asserted-by":"crossref","first-page":"3628","DOI":"10.1200\/JCO.2015.62.9394","article-title":"Feasibility of preoperative chemotherapy with or without radiation therapy in localized soft tissue sarcomas of limbs and superficial trunk in the Italian sarcoma group\/grupo Espanol de investigacion en sarcomas randomized clinical trial: Three versus five cycles of full-dose epirubicin plus ifosfamide","volume":"33","author":"Palassini","year":"2015","journal-title":"J Clin Oncol"},{"key":"2021122510435114600_onco12335-bib-0026","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2016.09.030","article-title":"(Neo)adjuvant treatment in localised soft tissue sarcoma: The unsolved affair","volume":"70","author":"Saponara","year":"2017","journal-title":"Eur J Cancer"},{"key":"2021122510435114600_onco12335-bib-0027","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1093\/annonc\/mdw430","article-title":"Short, full-dose adjuvant chemotherapy (CT) in high-risk adult soft tissue sarcomas (STS): Long-term follow-up of a randomized clinical trial from the Italian sarcoma group and the Spanish sarcoma group","volume":"27","author":"Gronchi","year":"2016","journal-title":"Ann Oncol"},{"key":"2021122510435114600_onco12335-bib-0028","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1200\/JCO.1994.12.6.1137","article-title":"Adjuvant CYVADIC chemotherapy for adult soft tissue sarcoma\u2013reduced local recurrence but no improvement in survival: A study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group","volume":"12","author":"Bramwell","year":"1994","journal-title":"J Clin Oncol"},{"key":"2021122510435114600_onco12335-bib-0029","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1093\/annonc\/mdu460","article-title":"Doxorubicin-based adjuvant chemotherapy in soft tissue sarcoma: Pooled analysis of two STBSG-EORTC phase III clinical trials","volume":"25","author":"Le Cesne","year":"2014","journal-title":"Ann Oncol"},{"key":"2021122510435114600_onco12335-bib-0030","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/S0959-8049(01)00083-1","article-title":"A randomised phase II study on neo-adjuvant chemotherapy for \u2018high-risk\u2019 adult soft-tissue sarcoma","volume":"37","author":"Gortzak","year":"2001","journal-title":"Eur J Cancer"},{"key":"2021122510435114600_onco12335-bib-0031","doi-asserted-by":"crossref","first-page":"e0158406","DOI":"10.1371\/journal.pone.0158406","article-title":"Survival impact of centralization and clinical guidelines for soft tissue sarcoma (a prospective and exhaustive population-based cohort)","volume":"12","author":"Derbel","year":"2017","journal-title":"PLoS One"},{"key":"2021122510435114600_onco12335-bib-0032","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1159\/000164692","article-title":"Primary and secondary care consultations in elderly demented individuals in France. Results from the Three-City Study","volume":"26","author":"Helmer","year":"2008","journal-title":"Dement Geriatr Cogn Disord"},{"key":"2021122510435114600_onco12335-bib-0033","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/nrclinonc.2013.110","article-title":"Liquid biopsy: Monitoring cancer-genetics in the blood","volume":"10","author":"Crowley","year":"2013","journal-title":"Nat Rev Clin Oncol"},{"key":"2021122510435114600_onco12335-bib-0034","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12885-016-2992-8","article-title":"Use of liquid biopsies to monitor disease progression in a sarcoma patient: A case report","volume":"17","author":"Namlos","year":"2017","journal-title":"BMC Cancer"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2017-0391","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2017-0391","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/23\/4\/461\/41915122\/oncolo_23_4_461.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/23\/4\/461\/41915122\/oncolo_23_4_461.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T10:44:59Z","timestamp":1640429099000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/23\/4\/461\/6439571"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,30]]},"references-count":34,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2017,11,30]]},"published-print":{"date-parts":[[2018,4,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2017-0391","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,4,1]]},"published":{"date-parts":[[2017,11,30]]}}}